The effect of oral royal jelly administration on skin barrier function: a double-blind randomized placebo-controlled trial

2018 ◽  
Vol 28 (4) ◽  
pp. 563-564 ◽  
Author(s):  
Chisa Nakashima ◽  
Atsushi Otsuka ◽  
Judith A. Seidel ◽  
Kenji Kabashima
Keyword(s):  
Barrier Function ◽  
Royal Jelly ◽  
Controlled Trial ◽  
Skin Barrier ◽  
Skin Barrier Function ◽  
Double Blind

Randomised double-blind placebo-controlled study of the effect of Lactobacillus paracasei NCC 2461 on skin reactivity

2014 ◽  
Vol 5 (2) ◽  
pp. 137-145 ◽  
Author(s):  
A. Gueniche ◽  
D. Philippe ◽  
P. Bastien ◽  
G. Reuteler ◽  
S. Blum ◽  
...  
Keyword(s):  
Barrier Function ◽  
Skin Barrier ◽  
The Body ◽  
Lactobacillus Paracasei ◽  
Controlled Study ◽  
Skin Barrier Function ◽  
Skin Sensitivity ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Function Recovery

In recent decades, the prevalence of subjects with reactive skin has considerably increased in industrialised countries. 50% of women and 30% of men report cutaneous discomfort classified under reactive/sensitive skin. Several topical approaches have been proposed, in particular through improvement of galenic forms or protection of epidermal surface. We propose to act differently, deeply from inside the body via an innovative nutritional approach. To this purpose, Lactobacillus paracasei NCC 2461 (ST11) was selected because of its specific beneficial skin properties discovered in in vitro studies, i.e. diminution of neurogenic inflammation and promotion of the recovery of skin barrier function. We designed a randomised double-blind placebo-controlled clinical study with a two-month supplementation in two female treatment groups (n=32 per group). A capsaicin test was performed to monitor the time course of skin sensitivity. Moreover, transepidermal water loss was assessed to analyse the rate of skin barrier function recovery; dryness of the leg and roughness of the cheeks was investigated by a dermatologist as well as by self-assessment. The results of the present clinical trial show that oral supplementation with the probiotic decreases skin sensitivity and increases the rate of barrier function recovery. Thus, the data provide evidence that daily intake of ST11 could improve reactive skin condition.

scholarly journals Clinical Evaluation of Topical Lotion Containing 2-Aza-8-Oxohypoxanthine on Skin Barrier Function against Water Loss

Cosmetics ◽  
2021 ◽  
Vol 8 (3) ◽  
pp. 83
Author(s):  
Hisae Aoshima ◽  
Rinta Ibuki ◽  
Masayuki Ito ◽  
Hirokazu Kawagishi
Keyword(s):  
Moisture Content ◽  
Stratum Corneum ◽  
Water Loss ◽  
Barrier Function ◽  
Statistical Difference ◽  
Skin Barrier ◽  
Comparative Trial ◽  
Skin Barrier Function ◽  
Double Blind ◽  
Split Face

A clinical study was conducted to evaluate the efficacy of 2-aza-8-oxohypoxanthine (AOH) on human skin in a double-blind, placebo-controlled, and split-face comparative trial. To this end, a topical lotion containing 0.1% of AOH and its placebo formulation were applied in 20 Japanese subjects (age: 41–58 years, average: 48.4 ± 4.7 years) to their faces daily for eight weeks. The moisture content in the stratum corneum and the trans-epidermal water loss (TEWL) were measured at the beginning of the study and after eight weeks. The results obtained upon comparing the data of the two measuring points showed that the 0.1% AOH lotion caused a statistically significant larger decrease in TEWL after eight weeks. Moreover, the 0.1% AOH lotion produced a larger increase in the moisture content in the stratum corneum after eight weeks, although there was no statistical difference between the two formulations. These results clearly indicate that AOH is effective as a cosmetic agent with a skin barrier function against water loss.

scholarly journals Retaining Skin Barrier Function Properties of the Stratum Corneum with Components of the Natural Moisturizing Factor—A Randomized, Placebo-Controlled Double-Blind In Vivo Study

Molecules ◽  
2021 ◽  
Vol 26 (6) ◽  
pp. 1649
Author(s):  
Johannes Schleusener ◽  
Andrew Salazar ◽  
Jörg von Hagen ◽  
Jürgen Lademann ◽  
Maxim E. Darvin
Keyword(s):  
Stratum Corneum ◽  
Barrier Function ◽  
Bound Water ◽  
Skin Barrier ◽  
Skin Barrier Function ◽  
Double Blind Study ◽  
Weakly Bound ◽  
Double Blind

The influence of a topically applied formulation containing components of natural moisturizing factor (NMF) on barrier-related parameters of the stratum corneum (SC) was investigated in vivo using confocal Raman microspectroscopy in a randomized, placebo-controlled double-blind study on 12 volunteers for 14 days. This method allowed for the elucidation of subtle differences between the verum and the placebo even though the components of the verum naturally occur in the SC. This differentiation is not possible non-invasively by conventional methods. In this study, we found that the applied verum and placebo formulations disrupted the equilibrium of water, NMF and lipids in the SC. The adverse effects of the formulation could be mitigated by incorporating it into a simplified supplementation of NMF molecules. As a long-term effect, the amount of strongly bound water increases at 30–40% SC depth (p < 0.05) and the amount of weakly bound water decreases at 30–40% SC depth (p < 0.05) for the verum. This supplement was also unexpectedly able to prevent intercellular lipids (ICL) disorganization in selected depths. In the long term, the verum treatment limited the lateral disorganization of the ICL to the upper 20% SC depth. Further research is required to elucidate the interplay of these factors in the SC, to better understand their contribution to the equilibrium and barrier function of the skin. This understanding of the interaction of these naturally occurring components could help in the future to develop and optimize topical treatments for diseases like psoriasis, atopic dermatitis, ichthyosis where the skin barrier is disrupted.

scholarly journals Randomized, Controlled Trial Evaluating a Baby Wash Product on Skin Barrier Function in Healthy, Term Neonates

2013 ◽  
Vol 42 (2) ◽  
pp. 203-214 ◽  
Author(s):  
Tina Lavender ◽  
Carol Bedwell ◽  
Stephen A. Roberts ◽  
Anna Hart ◽  
Mark A. Turner ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Barrier Function ◽  
Controlled Trial ◽  
Skin Barrier ◽  
Skin Barrier Function ◽  
Term Neonates ◽  
Randomized Controlled

scholarly journals PEBBLES study protocol: a randomised controlled trial to prevent atopic dermatitis, food allergy and sensitisation in infants with a family history of allergic disease using a skin barrier improvement strategy

BMJ Open ◽  
2019 ◽  
Vol 9 (3) ◽  
pp. e024594 ◽  
Author(s):  
Adrian Lowe ◽  
John Su ◽  
Mimi Tang ◽  
Caroline J Lodge ◽  
Melanie Matheson ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Food Allergy ◽  
Family History ◽  
Randomised Controlled Trial ◽  
Barrier Function ◽  
Controlled Trial ◽  
Skin Barrier ◽  
Skin Barrier Function ◽  
History Of ◽  
Randomised Controlled

IntroductionThe skin is an important barrier against environmental allergens, but infants have relatively impaired skin barrier function. There is evidence that impaired skin barrier function increases the risk of allergic sensitisation, atopic dermatitis (AD) and food allergy. We hypothesise that regular prophylactic use of emollients, particularly those that are designed to improve skin barrier structure and function, will help prevent these conditions. With the aim of determining if application of a ceramide-dominant emollient two times per day reduces the risk of AD and food allergy, we have commenced a multicentre phase III, outcome assessor blinded, randomised controlled trial of this emollient applied from birth to 6 months.Methods and analysisInfants (n=760) with a family history of allergic disease will be recruited from maternity hospitals in Melbourne. The primary outcomes are as follows: the presence of AD, assessed using the UK Working Party criteria, and food allergy using food challenge, in the first 12 months of life as assessed by a blinded study outcome assessor. Secondary outcomes are as follows: food sensitisation (skin prick test), skin barrier function, AD severity, the presence of new onset AD after treatment cessation (between 6 and 12 months) and the presence of parent reported AD/eczema. Recruitment commenced in March 2018.Ethics and disseminationThe PEBBLES Study is approved by the Human Research Ethics Committees of the Royal Children’s Hospital (RCH) (#37090A) and the Mercy Hospital for Women (2018–008). Parents or guardians will provide written informed consent. Outcomes will be disseminated through peer-reviewed publications and presented at scientific conferences.Trial registration numbersACTRN12617001380381 andNCT03667651.

Sign in / Sign up

Export Citation Format

Share Document